Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. (ACB) is a Canada-based global medical cannabis company with shares listed on NASDAQ and the Toronto Stock Exchange. From an investor and industry perspective, Aurora’s news flow centers on medical cannabis expansion, scientific research, international market development and operational performance.
Company announcements frequently highlight growth in global medical cannabis revenue, leadership positions in key markets, and updates on its plant propagation business through Bevo Farms Ltd. Earnings releases and financial updates provide detail on segment performance across medical cannabis, consumer cannabis and plant propagation, along with adjusted gross margins, adjusted EBITDA and working capital trends.
News items also cover Aurora’s international initiatives, such as investments in its EU-GMP manufacturing facility in Leuna, Germany, launches of proprietary medical flower cultivars in Poland under the Cannabis flos Aurora brand, and the introduction of the Daily Special medical brand in Germany. In Australia, updates include distribution partnerships through MedReleaf Australia and Leafio, aimed at expanding access to Aurora’s medical cannabis products via pharmacy networks.
Scientific and educational developments are another recurring theme. Aurora reports progress in powdery mildew resistance research (PM2) conducted at its Aurora Coast R&D facility, including breeding programs and production trials. The company also announces collaborations like the Physician Experience Platform (PEP) with Copeia, which provides anonymized, peer-reviewed medical cannabis case studies for physicians in multiple countries.
Investors following ACB news can expect coverage of quarterly results, international facility investments, product launches, distribution agreements, conference participation and medical education initiatives. Bookmark this page to monitor how Aurora’s strategic focus on global medical cannabis, science and international markets is reflected in its ongoing news and disclosures.
Aurora Cannabis (ACB) reported a Q2 2023 net revenue of $61.7 million, a 25% increase from Q1 2023, driven by growth across all cannabis segments and a full contribution from Bevo Agtech Inc. Additionally, the company achieved a positive Adjusted EBITDA of $1.4 million, marking a significant turnaround from previous losses. Aurora has realized approximately $340 million in annual cost savings since early 2020 and reduced debt by $302 million in 2022. Despite a net loss of $67.2 million, the company maintains a net cash position, with approximately $310 million in cash as of February 2023.
Aurora Cannabis Inc. (ACB) announced a conference call to discuss its second quarter financial results for fiscal year 2023, scheduled for February 9, 2023, at 5:00 p.m. ET. The financial results will be released after the market closes the same day. CEO Miguel Martin and CFO Glen Ibbott will host the call, which will also include a Q&A session. Investors can access the webcast through the company's investor info page. Aurora continues to serve both medical and consumer markets with a strong brand portfolio, emphasizing its commitment to high-quality cannabis products.
Aurora Cannabis closed the sale of its Aurora Polaris facility, generating approximately $15 million in gross proceeds. This sale is part of the company's ongoing transformation strategy. Following this transaction, Aurora maintains a strong balance sheet with about $320 million in cash and cash equivalents, including $63 million of restricted cash. The company expects to achieve Adjusted EBITDA profitability for the quarter ending December 31, 2022, further solidifying its position in the cannabis industry as a leader in both medical and consumer markets.
Summary not available.
Aurora Cannabis (ACB) announced the repurchase of approximately $102.5 million of its convertible senior notes for $99.4 million in cash, achieving a 4.5% discount. This marks a total repurchase of $316.5 million over the past year, leading to annual cash interest savings of $17.4 million. The company reports a strong balance sheet and aims to achieve Adjusted EBITDA profitability by December 31, 2022.
Aurora Cannabis Inc. (ACB) announced the results of its Annual General and Special Meeting held on November 14, 2022. A total of 92,937,078 shares, or 30.93% of issued shares, were represented. All proposed matters were approved, including the election of directors with high approval rates: Miguel Martin received 92.56% support, and Norma Beauchamp 83.50%. Shareholders also approved KPMG as auditors and amendments to several compensation plans. The voting results report is available on SEDAR.
Aurora Cannabis Inc. (NASDAQ: ACB) will discuss its Q1 fiscal year 2023 results on November 10, 2022, at 5:00 p.m. ET. The Company will announce its financial results after market close on the same day. Aurora continues to carve a niche in the cannabis industry, emphasizing quality and innovation in both medical and consumer markets. The conference call will feature CEO Miguel Martin and CFO Glen Ibbott, providing insights into the Company's financial performance and future outlook.
Aurora Cannabis (NASDAQ: ACB, TSX: ACB) has filed its management information circular in preparation for its annual and special meeting of shareholders on November 14, 2022. The materials, now being mailed to shareholders, outline the business to be discussed, voting instructions, and participation details. Key items for voting include the election of nine directors, the appointment of KPMG LLP as auditors, and amendments to the stock option plan. The Board recommends voting in favor of all proposals.
Aurora Cannabis (NASDAQ: ACB) announced a major fall product launch, expanding its portfolio across adult-use and medical markets. The lineup features innovative strains such as Electric Honeydew and Ultra Grape Kush, showcasing unique genetics and high-potency THC levels. The new products include high-potency gummies, flower, and infused pre-rolls. This marks Aurora's most substantial release in over two years, with over 60 new offerings becoming available in October.
Aurora Cannabis (NASDAQ: ACB, TSX: ACB) announced on October 7, 2022, a repurchase of approximately $31.3 million in convertible senior notes, costing $29.8 million in cash, including interest. This transaction aims to reduce the company's debt and annual cash interest costs, yielding annual savings of about $11.9 million. With roughly $380 million in cash and cash equivalents, Aurora's balance sheet remains robust, and the company expects to achieve a positive Adjusted EBITDA run rate by December 31, 2022.